Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.95 USD
Change Today -0.06 / -2.99%
Volume 147.2K
As of 8:10 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

photomedex inc (PHMD) Snapshot

Open
$2.00
Previous Close
$2.01
Day High
$2.07
Day Low
$1.91
52 Week High
04/25/14 - $15.88
52 Week Low
12/16/14 - $1.01
Market Cap
43.1M
Average Volume 10 Days
156.2K
EPS TTM
$-3.21
Shares Outstanding
22.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PHOTOMEDEX INC (PHMD)

photomedex inc (PHMD) Related Businessweek News

No Related Businessweek News Found

photomedex inc (PHMD) Details

PhotoMedex, Inc., a skin health company, provides integrated disease management and aesthetic solutions to dermatologists, professional aestheticians, and consumers in North America, the Asia Pacific, Europe, and South America. The company operates in three segments: Consumer, Physician Recurring, and Professional. It offers products and services that address skin diseases and conditions, including psoriasis, vitiligo, acne, and photo damage. The company also provides a range of home-use devices under the no!no! brand name for various indications, such as hair removal, acne treatment, skin rejuvenation, and lower back pain; and a professional product line for acne clearance, skin tightening, psoriasis care, and hair removal to physician clinics and spas. In addition, it offers Kyrobak that uses technology to treat unspecified, lower back pain; XTRAC ultraviolet (UV) light used for the treatment of psoriasis and other skin diseases; NEOVA skin care products for preventing premature skin aging due to UV-induced DNA damage; and Omnilux light therapy systems to treat wrinkles, acne, minor muscle pain, and pigmented lesions. Further, the company provides Lumière light therapy equipment for use in non-medical applications, as well as a line of topical lotions to enhance the appearance of fine lines, wrinkles, skin tone, and blemishes. Additionally, it develops, manufactures, and sells surgical products, including proprietary free-beam and Contact Laser systems for surgery under the PhotoMedex Surgical Products trade name. PhotoMedex, Inc. was founded in 1980 and is headquartered in Horsham, Pennsylvania.

179 Employees
Last Reported Date: 03/16/15
Founded in 1980

photomedex inc (PHMD) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $468.0K
President, Chief Financial Officer, Treasurer...
Total Annual Compensation: $353.0K
Compensation as of Fiscal Year 2014.

photomedex inc (PHMD) Key Developments

PhotoMedex, Inc. Provides Update on Class Action Lawsuit Settlement

PhotoMedex, Inc. served on December 20, 2013, with a purported shareholder derivative and class action lawsuit filed in the United States District Court for the Eastern District of Pennsylvania against the company and its two top executives, Dolev Rafaeli, Chief Executive Officer, and Dennis M. McGrath, President and Chief Financial Officer. The action alleged various violations of the Federal securities laws between November 7, 2012 and November 14, 2013, including that the company and its officers made false and misleading statements or failed to disclose material facts concerning the company's business. The plaintiffs sought class action status for the suit, as well as an unspecified amount of monetary damages, pre-and post-judgment interest and attorneys' fees, expert witness fees and other costs. A companion action was brought against the company and its two officers in the State of Israel, where the company's shares are traded on the Tel Aviv Stock Exchange. On March 11, 2015, the United States District Court for the Eastern District of Pennsylvania entered an order preliminarily approving a proposed settlement in this action. The proposed settlement provides a fund of $1.5 million for the benefit of those persons or entities who purchased securities issued by the company during the period November 6, 2012 and November 5, 2013, inclusive. The settlement fund will also pay for plaintiffs' counsel's fees and expenses approved by the court with respect to the action. The company maintains insurance that will help defray the cost of the proposed settlement, and does not expect the proposed settlement to have a material impact on its financial results. The proposed settlement is subject to final approval by the court. A hearing has been scheduled at 9:30 a.m., on July 20, 2015 to determine whether to approve the settlement, dismiss the action with prejudice, and provide for the payment of plaintiffs' counsel's attorney's fees and expenses, and consider an application for reimbursement of expenses (including lost wages) of the lead plaintiff.

Shepherd, Finkelman, Miller & Shah, LLP Announces Proposed Settlement of Class Action on Photomedex, Inc

Shepherd, Finkelman, Miller & Shah, LLP announced that the United States District Court for the Eastern District of Pennsylvania has approved the announcement of a proposed class action settlement that would benefit purchasers of PhotoMedex, Inc. Pursuant to an order of the United States District Court for the Eastern District of Pennsylvania, that this case has been certified as a class action for settlement purposes only, and a settlement with PhotoMedex, Dennis McGrath and Dolev Rafaeli in the amount of $1,500,000 has been proposed by the Settling Parties. A hearing will be held before the Honorable Paul S. Diamond, United States District Court for the Eastern District of Pennsylvania, 601 Market Street, Philadelphia, PA, Courtroom 6613 at 9:30 a.m., on July 20, 2015 to determine, among other things: whether the proposed settlement of this class action and the plan of allocation of settlement proceeds should be approved by the court as fair, reasonable, and adequate, whether, thereafter, this Litigation should be dismissed with prejudice as set in the Stipulation and Agreement of Settlement, dated as of January 9, 2015, and to consider the application of Plaintiffs' Counsel for attorneys' fees and reimbursement of expenses, and to consider the application for reimbursement of expenses (including lost wages) of the Lead Plaintiff. The Court has reserved the right to reschedule the hearing without further notice.

PhotoMedex, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

PhotoMedex, Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company announced revenues of $38,878,000 compared to $63,490,000 for the same period a year ago. Loss from continuing operations before interest and other financing expense, net was $5,181,000 compared to profit of $4,251,000 for the same period a year ago. Loss from continuing operations before income taxes was $6,618,000 compared to profit of $4,483,000 for the same period a year ago. Loss from continuing operations was $43,630,000 compared to profit of $3,185,000 for the same period a year ago. Net loss was $98,724,000 or $5.18 per basic and diluted share compared to net income of $3,185,000 or $0.16 per basic and diluted share for the same period a year ago. LBITDA was $59,105,000 compared to EBITDA of $6,092,000 for the same period a year ago. Non-GAAP adjusted loss was $1,651,000 or $0.09 per share compared to non-GAAP adjusted income of $7,282,000 or $0.37 per share for the same period a year ago. For the year, the company announced revenues of $163,541,000 compared to $224,664,000 for the same period a year ago. Loss from continuing operations before interest and other financing expense, net was $21,044,000 compared to profit of $22,045,000 for the same period a year ago. Loss from continuing operations before income taxes was $25,431,000 compared to profit of $22,747,000 for the same period a year ago. Loss from continuing operations was $61,743,000 compared to profit of $18,377,000 for the same period a year ago. Net loss was $121,496,000 or $6.41 per basic and diluted share compared to net income of $18,377,000 or $0.90 per basic and diluted share for the same period a year ago. Net cash used in operating activities was $24,171,000 compared to net cash provided by operating activities of $25,037,000 for the same period a year ago. Purchases of PP&E, net were $251,000 compared to $943,000 for the same period a year ago. LBITDA was $75,293,000 compared to EBITDA of $28,876,000 for the same period a year ago. Non-GAAP adjusted loss was $1,937,000 or $0.10 per share compared to non-GAAP adjusted income of $33,861,000 or $1.73 per share for the same period a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PHMD:US $1.95 USD -0.06

PHMD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cynosure Inc $31.14 USD -0.36
Koninklijke Philips NV €26.45 EUR -0.405
Syneron Medical Ltd $12.03 USD -0.11
Valeant Pharmaceuticals International Inc C$251.15 CAD -1.52
Zeltiq Aesthetics Inc $33.51 USD -0.04
View Industry Companies
 

Industry Analysis

PHMD

Industry Average

Valuation PHMD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.2x
Price/Book 0.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHOTOMEDEX INC, please visit www.photomedex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.